New Market Study: "Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2012"
Global Markets Direct's, 'Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL). Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, Half Year is built using...
View full press release